Iohexol
This non-ionic iodinated contrast agent is widely used for myelography (spinal imaging), cerebral and peripheral angiography, and CT scanning of various body systems. It is well tolerated due to its low osmolality and is considered safe for injection into the spinal canal. Adequate hydration before and after use is important to protect the kidneys.
Khối lượng phân tử
821,1000 g/mol
LogP
-3,00
TPSA
200,00 Ų
Lipinski RO5
Không đạt
Lĩnh vực điều trị
Cơ chế tác dụng
Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.
Cấu trúc 2D
Cite this structure
Embed this structure
SMILES
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I
InChI
InChI=1S/C19H26I3N3O9/c1-8(29)25(4-11(32)7-28)17-15(21)12(18(33)23-2-9(30)5-26)14(20)13(16(17)22)19(34)24-3-10(31)6-27/h9-11,26-28,30-32H,2-7H2,1H3,(H,23,33)(H,24,34)
Molecular Formula
C19H26I3N3O9
HBD / HBA
8 / 9
Liên kết có thể quay
12
Nguyên tử nặng
34
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Câu hỏi thường gặp
This non-ionic iodinated contrast agent is widely used for myelography (spinal imaging), cerebral and peripheral angiography, and CT scanning of various body systems. It is well tolerated due to its low osmolality and is considered safe for injection into the spinal canal. Adequate hydration before and after use is important to protect the kidneys.
Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.
Yes, Iohexol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200455. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3730. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="iohexol"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/iohexol/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/iohexol/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/iohexol/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="iohexol"></drugfyi-drug>